GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Days Sales Outstanding

Alere (ALRPRB.PFD) Days Sales Outstanding : 62.64 (As of Jun. 2017)


View and export this data going back to 2008. Start your Free Trial

What is Alere Days Sales Outstanding?

Alere's average Accounts Receivable for the three months ended in Jun. 2017 was $382.83 Mil. Alere's Revenue for the three months ended in Jun. 2017 was $557.67 Mil. Hence, Alere's Days Sales Outstanding for the three months ended in Jun. 2017 was 62.64.

The historical rank and industry rank for Alere's Days Sales Outstanding or its related term are showing as below:

ALRPRB.PFD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.13   Med: 67.28   Max: 79.93
Current: 59.13

During the past 13 years, Alere's highest Days Sales Outstanding was 79.93. The lowest was 59.13. And the median was 67.28.

ALRPRB.PFD's Days Sales Outstanding is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 69.32 vs ALRPRB.PFD: 59.13

Alere's Days Sales Outstanding declined from Jun. 2016 (66.27) to Jun. 2017 (62.64).


Alere Days Sales Outstanding Historical Data

The historical data trend for Alere's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere Days Sales Outstanding Chart

Alere Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.23 70.78 67.17 66.74 65.31

Alere Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.27 66.94 63.44 62.15 62.64

Competitive Comparison of Alere's Days Sales Outstanding

For the Diagnostics & Research subindustry, Alere's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Alere's Days Sales Outstanding falls into.



Alere Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Alere's Days Sales Outstanding for the fiscal year that ended in Dec. 2016 is calculated as

Days Sales Outstanding (A: Dec. 2016 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2015 ) + Accounts Receivable (A: Dec. 2016 )) / count ) / Revenue (A: Dec. 2016 )*Days in Period
=( (436.924 + 413.535) / 2 ) / 2376.335*365
=425.2295 / 2376.335*365
=65.31

Alere's Days Sales Outstanding for the quarter that ended in Jun. 2017 is calculated as:

Days Sales Outstanding (Q: Jun. 2017 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2017 ) + Accounts Receivable (A: Jun. 2017 )) / count ) / Revenue (A: Jun. 2017 )*Days in Period
=( (387.687 + 377.963) / 2 ) / 557.672*365 / 4
=382.825 / 557.672*365 / 4
=62.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alere  (NYSE:ALRPRB.PFD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Alere Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Alere's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere (ALRPRB.PFD) Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere (ALRPRB.PFD) Headlines

From GuruFocus

Corsair Capital's Investment Thesis on Alere Inc.

By Canadian Value Canadian Value 01-23-2014

Alere's Shareholders Approve Merger With Abbott

By Alberto Abaterusso Alberto Abaterusso 10-23-2016

Alere Reports 2nd Quarter

By Alberto Abaterusso Alberto Abaterusso 08-04-2017

Mario Gabelli Comments on Alere Inc

By Vera Yuan Vera Yuan 11-21-2014

3 Investors Sitting on Huge Cash Stockpiles

By Holly LaFon Holly LaFon 11-21-2017

5 Resilient Biotech Stocks to Buy for 2012

By Vatalyst.com Vatalyst.com 02-28-2012

Watsa Buys 19 Holdings in What He Calls 'Stock-Picker's Market'

By Holly LaFon Holly LaFon 11-14-2017

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 03-17-2015

Diamond Hill Select Fund Third Quarter 2014 Commentary

By Vera Yuan Vera Yuan 10-17-2014

Alere Inc.: Foreign Currency Translations and the Euro

By Carmine Romano Carmine Romano 12-21-2011